NCT06270030 - Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 4, 2024

Primary Completion Date

April 10, 2024

Study Completion Date

April 10, 2024

Conditions

Presbyopia

Interventions

DRUG

LNZ101 (Aceclidine /Brimonidine) ophthalmic solution

Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later

DRUG

LNZ100 (Aceclidine) ophthalmic solution

Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later

DRUG

Placebo (Vehicle) ophthalmic solution

Once daily from day 1 to day 8; Everyday, subject will be administered with 1 drop in each eye followed by another drop in each eye 2 minutes later

Trial Locations (1)

Shanghai General Hospital, Shanghai